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1. Introduction 
Peripheral arterial occlusive disease (PAOD) commonly results from progressive narrowing 
or occlusion of arteries in the lower extremities mostly due to atherosclerosis. The 
atherosclerotic process of progressive narrowing and hardening of arteries can occur in each 
artery in the human body, however it mainly affects coronary, cerebral and peripheral 
arteries especially those in the lower extremities(1). The preferential sites of involvement of 
PAOD are the femoral and popliteal arteries in 80-90%, the tibial and peroneal arteries in 40-
50% and in 30% the aorta and iliac arteries(2). The manifestation of PAOD ranges from no 
symptoms to tissue loss that may eventually requires amputation of an affected limb. The 
majority of patients with PAOD have asymptomatic or atypical disease (figure 1).  
Total disease prevalence based on objective testing has been evaluated in several 
epidemiologic studies and ranges from 3% to 10% in adults, increasing to 15 to 20% in 
persons over 70 years. PAOD increases progressively with age, beginning after the age of 
40(3). The relationship between PAOD prevalence and age was illustrated on data from the 
1999–2000 National Health and Nutrition Examination Survey (NHANES), an ongoing cross-
sectional survey of the civilian, non-institutionalized population of the United States. The 
prevalence of PAOD, defined as an ankle-brachial index (ABI) <0.90 in either leg, was 0.9% 
between the ages of 40-49, 2.5% between the ages of 50-59, 4.7% between the ages of 60-69, 
and 14.5% in ages 70 and older(3). These numbers indicate that PAOD affects more than 5 
million adults in the United States, while international guidelines reveal some 27 million 
affected individuals in North America and Europe(1). The PARTNERS study (PAOD 
Awareness, Risk, and Treatment: New Resources for Survival) screened 6979 subjects for 
PAOD using the ABI (with PAOD defined as an ABI of ≤0.90 or a prior history of lower 
extremity revascularization)(4). Subjects were evaluated in primary care practices in the 
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United States if they were above 70 years of age or between 50–69 years when presenting 
with a risk factor for vascular disease (smoking, diabetes). PAOD was detected in 1865 
patients (29% of the cohort). Classic claudication or symptomatic PAOD was present in only 
5.5% of the newly diagnosed patients with PAOD. Some 12.6% of the patients with a prior 
diagnosis of PAOD had claudication. Other studies have evaluated symptomatic and 
asymptomatic PAOD patients in the same population. The ratio of the two is independent of 
age and is usually in the range of 1:3 to 1:4(1). It may be concluded that PAOD is still growing 
as a clinical problem due to the increasingly aged population in developed countries.  
 
Legend to figure: PAD – peripheral arterial disease; CLI – critical limb ischemia; CV – cardiovascular; MI – myocardial 
infarction.  
Figure 1. 5 years disease prognosis in claudicants (adapted from TASC II guidelines (1)). 
2. Etiology of symptomatic PAOD (Intermittent Claudication) 
50 – 80 % of PAOD patients are symptomatic and because of their complaints most of them 
will present themselves at a patient outdoor clinic. Symptomatic PAOD patients will have in 
20-50% of the cases symptoms of typical intermittent claudication (IC, which means ‘to 
limp’) (figure 1). IC is defined as muscle discomfort in the lower limb reproducibly elicited 
by exercise and relieved by rest within 10 minutes(1).  
Patients with IC have sufficient blood flow at rest and, therefore do not experience limb 
symptoms at rest. With exercise, occlusive or narrowing lesions in the arterial supply of the 
leg muscles limit the increase in blood flow resulting in a mismatch of oxygen supply and 
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muscle metabolic demand that is associated with the symptom of claudication. This 
mismatch causes cramping or aching pain in the buttock, hip, thigh, calf or in rare occasions 
the foot, forcing the patient to pause. In rest, the oxygen debt can be redeemed and 
symptoms are relieved. In women, the incidence rates of IC are approximately 50% lower 
than in men(5). IC has an approximately 3% prevalence in the general population in patients 
aged 40 up to 6% in patients aged 60 years and increasing in older age(1).  
 
Vascular origin - Major causes
Atherosclerosis 
Thombosed aneurysm 
Arterial injury 
Arterial dissection 
Atheroembolism 
Thromboembolism 
Thromboangiitis obliterans (Buerger's disease) 
Vascular origin - Other causes
Aorto-iliac 
Retroperitoneal fibrosis 
Radiation fibrosis 
Tumor 
Takayasu’s disease 
Iliac 
Fibromuscular dysplasia 
Iliac endofibrosis (athletic injury) 
Iliofemoral 
Pseudoxanthoma elasticum 
Popliteal 
Popliteal entrapment 
Adventitial cystic disease 
Table 1. Etiology of lower extremity ischemia 
Nerve root compression 
Spinal stenosis 
Hip / foot arthritis 
Arthritic, inflammatory processes 
Compartment syndrome 
Venous claudication 
Symptomatic Bakers cyste 
Table 2. Common differential diagnoses of non – vascular origin. 
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Eventually any process that results in arterial stenosis or occlusion can cause symptoms of 
claudication, ischemic pain, or tissue loss but the vast majority of patients with claudication 
suffer from atherosclerosis. Aetiologies of lower extremity ischemia due to arterial stenosis 
or occlusion other than atherosclerosis are shown in table 1.  
Arterial aneurysms can be the source of embolic debris leading to arterial obstruction 
resulting in symptoms of lower extremity ischemia. Popliteal entrapment syndrome can also 
present with IC and should be suspected in the young patient who presents with 
claudication but lacks atherosclerotic risk factors. In endurance athletes, especially cyclists, 
an even more unusual cause of claudication is due to repeated trauma (stretching or 
kinking) of the external iliac artery which can result in endofibrosis of the vessel(6).  
Other diseases of non-vascular origin should also be considered in the differential diagnosis 
of leg pain (table 2). These include neurological, musculoskeletal and venous disorders. 
Neurological pain (“spinal claudication”) is predominantly due to neurospinal (eg, disc 
disease, spinal stenosis, tumor) or neuropathic causes (eg, diabetes, alcohol abuse). 
Musculoskeletal pain derives from the bones, joints, ligaments, tendons, and fascial 
elements of the lower extremity. Clinical history taking and physical examination can help 
distinguish between some of the less common causes of these disorders, which is important 
to instate an effective treatment for a patient with IC complaints. 
3. Prognostics and mortality 
PAOD and IC are strong predictors for coinciding atherosclerotic disease and related 
mortality. The prevalence of cerebrovascular disease in patients with PAOD is about 25-
50%(7). The 10-year mortality rate due to cardiovascular disease is 62% for men with PAOD 
compared to 17% in the population of men without PAOD. For women with PAOD the 10-
year mortality rate is 33% compared to 12% without PAOD(8). In a subgroup of patients 
with severe and symptomatic PAOD a 15-fold increase in mortality rate was found(8).  
For IC, a 5-year mortality rate of 19.2 % is described, of which 70% is due to cardiovascular 
causes. Non-fatal cardiovascular events (e.g. myocardial infarction, stroke) in patients with 
IC are found in 29% at 5 years of follow-up(5). Compared to patients with IC, subjects with 
asymptomatic PAOD appear to have the same increased risk of cardiovascular events and 
death(5). Nonetheless, for those afflicted, IC impacts negatively on walking ability and 
health-related quality of life (QoL)(9, 10).  
4. General management of PAOD 
PAOD comes with serious health risks. An overall strategy and basic treatment is well 
described in several international guidelines like the American College of Cardiology/ 
American Heart Association (ACC/AHA) and Trans-Atlantic Inter-Society Consensus on 
Management of Peripheral Arterial Disease (TASC II)(1, 11). Treatment of PAOD should 
consist of a multicomponent therapy of cardiovascular risk reduction (1) including 
lifestyle coaching (2) and symptomatic treatment (3). The first two components aim to 
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prevent cardiovascular events (myocardial infarction, stroke) and related morbidity and 
mortality. The most important modifiable risk factors for atherosclerosis are smoking, 
hypertension, diabetes mellitus, hyperlipidemia and obesity(12). The third component is 
to improve QoL and realized with daily exercise supplemented with supervised exercise 
therapy (SET).  
5. Smoking cessation 
Smoking is a potent risk factor for symptomatic PAOD, with an important and consistent 
dose-response relationship(13). The prevalence of symptomatic PAOD was increased 2.3-fold 
in current smokers. Even in former smokers the prevalence was substantially increased by a 
factor of 2.6. Smoking cessation is associated with a decline in the incidence of IC. Results 
from the Edinburgh Artery Study found that the relative risk of IC was 3.7 in smokers 
compared with 3.0 in ex-smokers (who had discontinued smoking for less than 5 years)(1). In 
a meta-analysis of 12,603 smokers who had prior MI, CABG, angioplasty, or known coronary 
heart disease, the relative risk of mortality for quitters compared with those who continued to 
smoke was 0.64 (95% CI 0.58-0.71)(14). Observational studies have found that the risk of 
death, myocardial infarction and amputation is substantially greater, and lower extremity 
angioplasty and open surgical revascularization patency rates are lower in individuals with 
PAOD who continue to smoke than in those who stop smoking(15). Efforts to achieve 
smoking cessation are recommended for patients with lower extremity PAOD(13). A 
physician advice coupled with frequent follow-up achieves 1-year smoking cessation rates of 
approximately 5% compared with only 0.1% in individuals who try to quit smoking without 
a physician’s intervention(16). In patients with PAOD, comprehensive smoking cessation 
programs that included individualized counseling and pharmacological support significantly 
increased the rate of smoking cessation at 6 months compared with verbal advice to quit 
smoking (21.3% versus 6.8%, p<0.02)(17). Therefore the focused update of the guideline for 
the management of smoking patients recommended that current smokers or former smokers 
should be asked about their status of tobacco use at every visit (Level of Evidence: A). 
Furthermore patients should be assisted with counseling and developing a plan for quitting 
that may include pharmacotherapy and/or referral to a smoking cessation program(15). 
6. Hypertension 
Hypertension is a major risk factor for PAOD. However, data evaluating whether 
antihypertensive therapy alters the progression of claudication are lacking. Nevertheless, 
international guidelines support the treatment of hypertension in patients with PAOD to 
reduce morbidity from cardiovascular and cerebrovascular disease. In this high-risk group 
the current recommendation is a goal of 140/90 mmHg, or even 130/80 mmHg if the patient 
also has diabetes or renal insufficiency. In PAOD, thiazides and ACE inhibitors should be 
considered as initial blood-pressure lowering drugs to reduce the risk of cardiovascular 
events. Beta-adrenergic blocking drugs have been discouraged in PAOD because of the 
possibility of worsening claudication symptoms. In a Cochrane review there was no 
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supporting evidence that beta blockers adversely affect walking distance in people with 
IC(18). However, due to the lack of large published trials beta blockers should be used with 
caution but are not contraindicated in PAOD.  
7. Diabetes mellitus 
Diabetes increases the risk of PAOD approximately three- to four-fold, and the risk of 
claudication two-fold. Diabetes is also associated with peripheral neuropathy which may lead 
to an increased risk of foot ulcers and foot infections. In recent years, there has been much 
discussion about the optimal treatment strategy of type 2 diabetes mellitus, aggressive or 
standard glucose lowering therapy. In a meta-analysis, an intensive glucose lowering regime 
(glycated haemoglobin level below 6.0%) was compared to standard therapy (targeted a level 
of 7.0-7.9%) in type 2 diabetes mellitus. Overall, intensive therapy significantly reduced 
coronary events without a significant effect on events of stroke or all-cause mortality(19). 
However, aggressive control of blood glucose levels (glycated haemoglobin level below 6.0%) 
is not recommended. The long term results of intensive therapy described a significantly 
reduced nonfatal myocardial infarction risk but an increased all-cause mortality rate (hazard 
ratio 1.21; 95% C.I. 1.02-1.44) after 5-year related with aggressive glucose lowering(20). TASC II 
recommends moderate aggressive control of blood glucose levels with an A1C goal of <7.0% 
and as close to 6.0% as possible (but not below 6%)(1). 
8. Hyperlipidemia 
In case of hyperlipidemia, dietary modification should be the initial intervention to control 
abnormal lipid levels. A 2007 Cochrane meta-analysis of mostly older trials that specifically 
evaluated patients with lower limb atherosclerosis concluded that lipid-lowering therapy 
reduced disease progression (improvement in total walking distance (Mean Difference (MD) 
152 m; 95% CI 32.11 to 271.88) and pain-free walking distance (WMD 89.76 m; 95% CI 30.05 
to 149.47) but no significant impact on ankle brachial index (WMD 0.04; 95% CI -0.01 to 
0.09)(21). It was concluded that lipid-lowering therapy is effective in reducing 
cardiovascular mortality and morbidity in people with PAOD. It may also improve local 
symptoms. Until further evidence on the relative effectiveness of different lipid-lowering 
agents is available, use of a statin in people with PAOD and a blood total cholesterol level ≥ 
3.5 mmol/litre is indicated. One of the largest included studies in this Cochrane review, the 
Heart Protection Study demonstrated the benefits of cholesterol-lowering statin therapy in 
6.748 patients with PAOD and 13.788 other high-risk participants, allocation to 40 mg 
simvastatin daily reduced the rate of the first major vascular events by about one-quarter, 
and that of peripheral vascular events by about one-sixth, with large absolute benefits seen 
in participants with PAOD because of their high vascular risk. Consequently, according to 
this study statin therapy should be considered for all patients with PAOD (all patients with 
total cholesterol level ≥ 3.5 mmol/L). This is in contrast to the older ACC/AHA guidelines as 
they recommended achieving an LDL cholesterol level <2.59 mmol/L (<100 mg/dL) in all 
patients with PAOD. In patients with PAOD and a history of other vascular disease (i.e., 
 
The Role of Supervised Exercise Therapy in Peripheral Arterial Obstructive Disease 61 
coronary heart disease and cerebrovascular disease) it is reasonable to lower LDL 
cholesterol levels to 1.81 mmol/L (70 mg/dL)(11). Statins should be the primary lipid-
lowering agents to lower LDL cholesterol levels.  
9. Blood homocysteine 
Elevated homocysteine blood levels are associated with cardiovascular disease but it is 
uncertain whether this association is causal. Studies investigating the effects of folic acid 
supplementation on major vascular events in patients with peripheral arterial disease are 
lacking. However, long-term reductions in blood homocysteine levels with folic acid and 
vitamin B12 supplementation did not lead to a reduction of cardiovascular events and seems 
therefore not indicated according to a RCT including 12.064 survivors of myocardial 
infarction (22). 
10. Antiplatelet therapy 
Antiplatelet therapy reduces major vascular events (vascular death, nonfatal MI and 
nonfatal stroke) in patients with PAOD by 23%(23). Therefore, all symptomatic patients with 
or without a history of other cardiovascular disease should be prescribed antiplatelet 
therapy on the long term. Antiplatelet therapy is indicated to reduce the risk of MI, stroke 
and vascular death in individuals with symptomatic atherosclerotic lower extremity PAOD, 
including those with claudication. Aspirin is the antiplatelet agent of choice; clopidogrel 
may be used if aspirin cannot be tolerated or in the subgroup of patients with symptomatic 
PAOD(1). Unfortunately, adherence to cardiovascular medication is fairly low(24). Self-
reported consistent use (reported on ≥2 consecutive follow-up surveys and then through 
death, withdrawal, or study end) of cardiovascular medication was analysed using the Duke 
Databank for Cardiovascular Disease in patients with coronary artery disease with or 
without heart failure. In 2002, consistent use was reported: for aspirin, 71%; beta-blockers, 
46%; lipid-lowering therapy, 44%; aspirin and beta-blockers, 36%; and all three, 21%. For 
these reasons the assessment of medication compliance should be incorporated in the 
standard care for patients with PAOD, which is not the case in contemporary guidelines.  
11. Pharmacological therapy for Intermittent Claudication 
Pharmacologic treatment for relief of claudication symptoms typically involves other drugs 
than those used for risk reduction. Cilostazol is currently the most effective drug for IC(25). 
Approved by the FDA in 1999, the primary action of cilostazol is to inhibit 
phosphodiesterase type 3, which results in vasodilatation and inhibition of platelet 
aggregation, arterial thromboses and vascular smooth muscle proliferation. A three to six-
month course of cilostazol is a possible first line pharmacotherapy for the relief of 
claudication symptoms. One study with 2702 patients having stable moderate to severe 
claudication were randomly assigned to cilostazol or placebo. Patients treated with 100 mg 
cilostazol twice daily for 12 to 24 weeks experienced significantly greater increases in 
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maximal and pain-free walking distances (50% and 67%, versus 22% and 40%, respectively) 
compared to the placebo group(25). Naftidrofuryl can also be considered. In a meta-analysis, 
naftidrofuryl showed an clinically meaningful improvement in pain-free and maximum 
walking distance in patients with IC(26). It is a 5-hydroxytryptamine type 2 antagonist and 
may improve muscle metabolism and reduce erythrocyte and platelet aggregation. 
Approval of cilostazol or naftidrofuryl for IC is however limited to certain countries.  
Other treatments are described such as the use of pentoxifylline (Trental). Pentotoxifylline is 
a rheologic modifier approved by the FDA for the symptomatic relief of claudication. Its 
mechanism of action includes an increase in red blood cell deformity wheras it decreases 
fibrinogen concentration, platelet adhesiveness, and whole-blood viscosity. The available 
data indicate that the benefit of pentoxifylline is marginal and not well established(11).  
Ginkgo biloba has been studied in patients with claudication with modest success. The 
mechanism by which ginkgo may work in this disorder is unclear, but may involve a 
number of activities including an antioxidant effect, inhibition of vascular injury, and 
antithrombotic effects. In a meta-analysis of 11 trials, patients who received ginkgo biloba 
extract had no significant differences in initial claudication distance. However, a trend 
toward improvement in the absolute claudication distance was observed. With the treadmill 
distances standardized between the protocols, a mean difference of 3.57 (95% CI -0.10-4.19) 
was found that corresponded to about 200 feet (64 meters), but the difference was not 
significant(27). The TASC guidelines concluded that no effect was proven(1). Several studies 
have evaluated the role of Vitamin E, chelation therapy, omega-3 fatty acids and estrogen 
therapies in the treatment of claudication. However, none of these therapies appeared 
effective(1). 
12. Exercise therapy 
Exercise therapy is the first suggested therapy for patients with IC. In 1898 the German 
neurologist Wilhelm Erb described successful results of exercise therapy for a patient with 
IC(28). The first randomised clinical trial (RCT) was performed by Larsen en Lassen in 
1966(29). In this study, 7 patients treated with exercise therapy were compared with a 
control group of 7 patients who were given ‘medical treatment’ in the form of lactose tablets. 
For the group treated with exercise, a significant increase in maximum walking time was 
observed whereas the patients in the control group did not improve.  
Nowadays, exercise therapy for patients with IC is extensively studied. In a Cochrane review 
by Watson et al. exercise therapy was compared with usual care or placebo regarding data of 
functional capacity outcome measurements(30). A total of twenty-two trials met the inclusion 
criteria involving a total of 1200 participants. Compared to placebo and usual care, exercise 
therapy significantly improved maximal walking time with a mean difference of 5.12 minutes 
(95% confidence interval 4.51 – 5.72) and an improved maximum walking distance of 113.2 
metres (range 95.0 to 131.4). Exercise therapy also showed a positive effect on the reduction of 
cardiovascular risk factors including hypercholesterolemia, hypertension, and diabetes 
mellitus.  
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The most common exercise therapy prescription consists of a single oral advice, usually 
without supervision or follow-up. The adherence of patients given an oral exercise advice 
appears to be low. Comorbidity, lack of (specific) advice, fear, and lack of discipline and 
supervision are barriers to actually perform regular walking exercise(31). For these reasons 
the importance of supervision was recognised.  
13. Supervised exercise therapy vs usual care (exercise therapy) 
Supervised exercise therapy (SET) entails adequate coaching by a physical therapist (PT) or 
an other exercise specialist (e.g. exercise physiologist, exercise therapist, specialised 
cardiovascular nurse) and aims to increase maximal walking distance, physical activity and 
health-related QoL. The most effective programs employ treadmill walking of sufficient 
intensity to cause claudication symptoms. Exercise is continued till near maximum pain, 
followed by rest, and then a next cycle of exercise is started over the course of a 30–60 
minute session. During the exercise session, treadmill exercise is performed at a speed and 
grade that will induce claudication symptoms. The patient should stop walking when 
claudication pain is considered moderate (a less optimal training response will occur when 
the patient stops at the onset of claudication). Exercise sessions are typically conducted three 
times a week for 3 months. A Cochrane review by Bendermacher et al. compared SET with 
non-supervised exercise programmes for patients with IC(32). SET showed statistically 
significant and clinically relevant differences in improvement of maximal walking distance 
compared with non-supervised exercise therapy regimens, with an overall effect size of 0.58 
(95% confidence interval 0.31 to 0.85) at three months. This translates into an improvement 
of approximately 150 meters of maximum walking distance in favour of the supervised 
group. However, additional studies on QoL are needed to definitely demonstrate clinical 
effectiveness. 
Another systematic meta-analysis comparing supervised to unsupervised exercise therapy 
showed a weighted mean difference in Pain Free Walking Distance (PWD) and Absolute 
Walking Distance (AWD) of 143.8 meters (95% CI; 5.8e281.8) and 250.4 meters (95% CI; 
192.4-308.5), respectively. The authors concluded that SET increased the PWD and AWD 
more than standard care(33). In a recent randomized controlled trial, three groups were 
compared: usual care (walk advice), home-based exercise and supervised exercise(34). 
Claudication Onset Time (COT) and Peak Walking Time (PWT) were compared after 3 
months. A significant improvement in COT and PWT were obtained in the exercise groups, 
but not in the usual care group (change after 3 months (sec): usual care; COT -16s, PWT -10s; 
home-based; COT 134s, PWT 124s; supervised; COT 165s, PWT 215s).  
14. Supervised exercise therapy vs endovascular revascularisation 
A recent systematic review compared (S)ET with percutaneous transluminal angioplasty 
(PTA) in patients with intermittent claudication (IC) to obtain the best estimates of their 
relative effectiveness(35). Eleven studies (reporting data on eight randomized clinical trials) 
met the inclusion criteria. One trial included patients with isolated aortoiliac artery 
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obstruction(36). In this MIMIC trial, patients were randomised to receive either PTA or no 
PTA against a background of SET and best medical therapy. The maximum walking 
distance was 75% greater in the PTA group (95%; CI 2-202) at 6 months and 78% greater in 
the PTA group (95%; CI 0-216) (p=0.05) at 24 months. No benefits were found for health-
related QoL. Unfortunately this trial did not evaluate results of SET alone versus PTA alone, 
so there is no evidence that angioplasty alone would produce similar results. 
In the review of Frans et al. three trials were included, which studied SET and PTA in 
femoropopliteal artery obstructions. In summary, SET with additional PTA gave the best 
improvement in Maximal Walking Distance (MWD), Initial Claudication Distance (ICD) and 
Ankle Brachial Index (ABI)(35). Changes in MWD, ICD and ABI between PTA alone and 
SET alone were equivocal, either comparable or in favour of PTA. QoL improved 
significantly during follow-up compared with baseline of all treatments, without differences 
between both groups.  
The systematic review additionally included five trials that studied combined lesions(35). In 
summary, PTA plus SET compared with PTA alone demonstrated an improvement in 
MWD. The two trials evaluating SET versus PTA had inconsistent results: one showed a 
benefit in terms of MWD and ICD after SET. The other trial demonstrated equal benefit in 
both groups. QoL data was assessed by seven different instruments with equivalent results. 
In conclusion there is not yet a well defined consensus for tailoring the optimal treatment for 
lesions at different anatomical locations. International guidelines (TASC II) still suggests to 
perform revascularisation when proximal lesions are suspected instead of prescribing SET 
and medical therapy. Unfortunately these guidelines may seem outdated. Results described 
above one could conclude that, in general, the effectiveness of PTA and SET was equivalent, 
although PTA plus SET improved walking distance and some domains of QoL scales 
compared with SET or PTA alone(35). Evidence to use a combination of PTA and SET for 
patients with IC complaints is still inconclusive. Moreover, cost-effectiveness data is still 
missing.  
In the United States, another large multicenter RCT was conducted(37). In this so called 
CLEVER trial, the researchers aimed to find the optimal treatment strategy for IC with 
endpoints being maximal walking duration and health-related QoL. They randomly 
assigned 111 patients with aortoiliac peripheral artery disease to receive 1 of 3 treatments: 
optimal medical care (OMC), OMC plus supervised exercise (SE), or OMC plus stent 
revascularization (ST). At the 6-month follow-up, the change in peak walking time (the 
primary end point) was greatest for SE, intermediate for ST, and least with OMC (mean 
change versus baseline, 5.8±4.6, 3.7±4.9, and 1.2±2.6 minutes, respectively; P<0.001 for the 
comparison of SE versus OMC, P<0.02 for ST versus OMC, and P<0.04 for SE versus ST). 
QoL improved with both SE and ST compared with OMC, for most scales, the extent of 
improvement was greater with ST than SE. The authors concluded that SE results in 
superior treadmill walking performance than ST, even for those with aortoiliac peripheral 
artery disease(37). The contrast between better walking performance for SE and better 
patient-reported quality of life for ST warrants further follow up.  
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In conclusion, combining results of both studies, one could suggest that all patients with 
symptomatic PAOD should receive SET first as part of the initial treatment regimen, even 
patients with proximal lesions. In case of failing (patient dissatisfaction, disappointing 
results) an additional PTA could be suggested. However this treatment advice is based on 
moderate-level evidence, therefore results of two new trials have to be awaited (see section 
“future perspectives”).  
15. Supervised exercise therapy versus surgical reconstruction 
Only one RCT compared SET to surgical reconstruction(38). This study reported the initial 
evaluation of treatment efficiency in 75 patients with IC who were randomized to three 
treatment groups: 1) reconstructive surgery, 2) reconstructive surgery with subsequent 
physical training, and 3) physical training alone. The walking performance was improved in 
all three groups at follow-up, 13±0.5 months after randomization. Surgery was most 
effective, but the addition of training to surgery improved the symptom-free walking 
distance even further. However, no significant difference was found. Moreover, a higher 
complication rate and 3 deaths were observed in the surgical groups while no complications 
occurred in the trained group. Furthermore, the methodological quality of this trial could be 
questioned. 
16. Long term effects of supervised exercise therapy  
Few studies consider the long-term (>12 months) effects of SET. Gardner et al. tried to 
determine whether improvements in physical function after 6 months of SET could be 
sustained over a subsequent 12-months in older patients with IC(39). They concluded that 
improvements in maximum walking distance and physical activity level, after 6 months of 
exercise training, were prolonged for an additional 12 months period using a less intense 
exercise maintenance program. Ratliff et al. reported a 3-year follow-up of 212 patients with 
IC who initially were treated with SET with an exercise programme of two sessions a week 
for 10 weeks(40). Their results show that the maximum walking distance observed at 12 
weeks was still present at three years. Based on this limited experience, it appears that SET 
may have long term benefits for patients with IC.  
17. Supervised exercise therapy in hospital or community based setting  
An outpatient hospital setting was offered in the majority of all reviewed studies on SET. 
This approach may seem appropriate in trials but is associated with several limitations in 
daily clinical practise. First, the capacity of an exercise therapy program in an outpatient 
clinic is limited and not sufficient to provide SET for all patients with IC. Second, attending 
a hospital 3 times a week leads to a considerable transportation fee and is time-consuming 
for an individual patient. For this reason, implementation of a community-based SET 
program was instigated(41). The first results of a cohort study of patients treated with 
community-based SET resulted in a highly statistically significant improvement in 
 Vascular Surgery – Principles and Practice 66 
maximum walking distance (on a treadmill) after 3 and 6 months(42). The authors 
concluded that comparison of these results with historical studies on hospital-based SET 
should be done with caution due to the variability in the prescribed exercise regimens and 
used treadmill walking tests. However, SET in a community-based setting seemed to be at 
least as efficacious as programs that are provided in a clinical setting but with a higher 
capacity. 
18. Cost effectiveness of SET 
In a multicenter RCT ‘ExitPAD’ trial, Nicolaï et al. compared exercise therapy in the form of 
a ‘go home and walk’ advice (WA) with community-based SET for patients with IC(43). The 
data from this ExitPAD trial were also used to assess the cost-effectiveness of SET versus 
WA. For community-based SET, the incremental cost-effectiveness ratio for cost per QALY 
was €28,693. The Health Council of the Netherlands has determined that a QALY € 40,000 
may cost if the burden of disease for symptomatic PAOD is stated at a value of 0.5. At a 
willingness-to-pay threshold of this €40,000 SET seemed a cost-effective therapeutic option 
for patients with PAOD. In another randomized cost-effectiveness analysis SET was 
compared with endovascular revascularization (angioplasty with or without stenting)(44). 
This study was unfortunately underpowered so no significant difference was obtained. 
Endovascular revascularization leaded to a non-significant increase of 0.01 in QALYs (CI -
0.05 to 0.07). However a significant difference was demonstrated with respect to treatment 
costs. The costs for endovascular revascularization were significantly higher with a mean 
difference of € 2,318 per patient. In conclusion, endovascular revascularization was found 
cost effective if society would be willing to pay € 231,800 per QALY. This amount is far 
above the threshold of € 40,000. Therefore endovascular revascularization seems not cost 
effective compared with SET. 
Over the last decades, no international randomized cost-effectiveness analyses or health 
economic models were carried out to configure satisfying treatment strategies or guidelines. 
This while scientific evidence on the effectiveness of SET compared to endovascular 
revascularization has grown. Furthermore, the costs of endovascular revascularization will 
increase significantly as a result of technological innovations. SET seems the most cost-
effective treatment for symptomatic PAOD certainly if potential positive effects due to 
lifestyle changes on other vascular diseases (such as heart failure, myocardial infarction, 
stroke) and reduction of risk factors (such as hypertension, diabetes mellitus, and 
hyperlipidaemia) are taken into count. Further research into the extent of cost effectiveness is 
an urgent need for policy choices in modern health care (see section future perspectives)(45). 
19. Future perspectives 
Although SET is considered the best evidence based therapy for all patients with IC, general 
practitioners, vascular surgeons or vascular specialists do not always have the disposal of 
(community-based) physical or exercise therapists (PTs) with specific knowledge of IC or 
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exercise training. Also, not all PT’s have sufficient experience with this specific patient 
category. Patients suffer from a variety of comorbidities and modifiable lifestyle factors, 
potentially generating suboptimal results. Unfortunately, too many examples of PT’s treating 
patients with IC with massage and other alternative, non evidence based treatments exist.  
In an ideal situation, all patients with symptomatic PAOD should receive an evidence based 
standardised form of SET by an exercise specialist. Due to lack of capacity, hospital-based 
exercise therapy should be reserved for cases with severe (cardiac) comorbidity. For this 
reason the ClaudicatioNet concept was launched in the Netherlands in January 2011. 
ClaudicatioNet is a concept representing an integrated care network between PTs, vascular 
surgeons and general practitioners. ClaudicatioNet aims to implement nationwide coverage 
of regional networks providing transparent, synergistic and multidisciplinary care 
according the guidelines of cardiovascular risk management and SET.  
Two Dutch multicenter RCT’s are including patients to evaluate the effectiveness and cost-
effectiveness of SET. The ERASE-trial compares SET with a PTA complementary to SET. The 
optimal treatment strategy for IC due to an iliac artery obstruction will be determined in the 
SUPER-trial. The SUPER-trial compares the (cost-) effectiveness of initial PTA versus initial 
SET in patients with disabling IC due to an iliac artery obstruction. Results have to be 
awaited. 
Although there is little evidence yet, SET could also be effective for patients with critical 
limb ischemia as an adjuvant to a revascularisation procedure. Badger et al. evaluated the 
efficacy of an exercise program following arterial bypass surgery for short distance IC or 
critical ischemia(46). SET resulted for this group in an increased maximum walking distance 
of 175% compared to 4% for the group with usual care. These studies indicate that SET is a 
useful adjunct after a PTA or lower limb bypass surgery. In the Netherlands the PEARL 
study is designed to confirm the clinical effectiveness of SET after a vascular intervention for 
the subgroup of patients with critical limb ischemia. 
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